In a remarkable collaboration, Viralgen partners with Elaaj Bio to expedite gene therapy solutions for CDKL5 Deficiency Disorder, targeting critical needs in rare pediatric care.

Viralgen and Elaaj Bio announce a partnership aimed at developing a gene therapy for the rare pediatric condition known as CDKL5 deficiency. Their work is crucial for accelerating clinical development.

In a pivotal collaboration, Viralgen and Elaaj Bio align their expertise to drive the development of innovative gene therapy targeting CDKL5 deficiency disorder, aiming for clinical advancement.

Viralgen collaborates with Elaaj Bio to push forward a pioneering gene therapy program for CDKL5 Deficiency Disorder, aiming for clinical development.

Viralgen collaborates with Elaaj Bio to enhance a gene therapy program for CDKL5 deficiency disorder, a rare neurological condition affecting children.